Drug Profile
Erythropoietic protoporphyria gene therapy
Latest Information Update: 08 Jul 2003
Price :
$50
*
At a glance
- Originator Genetix Pharmaceuticals
- Developer Genetix Pharmaceuticals; Nonindustrial source
- Class Gene therapies
- Mechanism of Action Ferrochelatase synthesis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Erythropoietic protoporphyria
Most Recent Events
- 08 Jul 2003 Discontinued - Preclinical for Erythropoietic protoporphyria in USA (Unspecified)
- 27 Sep 1999 New profile
- 27 Sep 1999 Preclinical development for Erythropoietic protoporphyria in USA (Unspecified)